Danish biotech ADCendo ApS believes it can create a pipeline of antibody-drug conjugates targeting the novel cancer target uPARAP, bringing a lead candidate into clinical trials probably by 2023 using funds raised last month through a €51m ($62m) series A financing.
Founded in 2017, ADCendo has been supported from the start by Novo Seeds, and incubated since 2018 at the BioInnovation Institute, located in the country’s capital
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?